AIVIS Qanti IHC

Qanti IHC is an AI-powered solution for the quantification of ER, PR, HER2, and Ki-67 in breast cancer, offering a practical, reliable, flexible, and pathologist-friendly experience.
Qanti IHC
AI-Powered Quantification for Precision Medicine
MFDS (K-FDA) Approved
AI-Based Automatic Quantification of ER, PR, HER2 and Ki-67
Fast and Reliable Performance
- Qanti IHC analyzes each WSI in just 5 minutes.
- Check your result within seconds after drawing region-of-interest (ROI).
- Trained and validated on high-quality data from 10 in-house pathologists.
- Detecting entire cells instead of only nuclei to prevent overcounting.


Quick and Efficient Search for Positive Cells
- Qanti IHC can locate areas containing IHC-positive cells.
- Save your time and effort in identifying eligible patients for target therapy.
Hotspot Visualization
- Qanti IHC displays IHC-positive cell distribution as a heatmap.
- Quickly identify ‘hotspots’ for precise risk assessment.


One-Click Report Generation
- Qanti IHC generates a standardized quantification report based on ASCO/CAP guidelines.
- Review and customize the results as needed.
Practical Solution
- Processes each whole slide image (WSI) in under 5 minutes.
- Get ready-made results within seconds after drawing a region of interest (ROI).
Reliable
- Trained and validated by a team of 10 full-time in-house pathologists.
- Extensively tested on slides from diverse scanners and sources.
Flexible
- Capable of visualizing over 3,000,000 cells at once.
- Performs WSI-level cell proportion calculations for comprehensive quantification.
Pathologist-Friendly
- Easy to view and modify results
- Standardized ROI drawing tools, including 2mm² and HPF (high-power field) area stamps.

More Solutions from Aivis
Compare Solutions
Get Pathology News Delivered to Your Inbox
Learn More
Aivis News
AIVIS Presents Breast Cancer Biomarker Ki-67 Digital Pathology AI Validation Study at ESMO Breast Cancer 2026
Editor2026-06-02T15:11:15+00:00May 12, 2026|
AimedBio Announces Strategic Investment and Joint Research with AIVIS in AI-Based Biomarker Quantification
Editor2026-03-02T13:42:58+00:00February 25, 2026|
AIVIS Presents Large-Scale Study on AI-Assisted HER2 Reading for Breast Cancer at ESMO ASIA 2025
Editor2026-02-05T09:45:08+00:00January 19, 2026|
AIVIS Highlights AI Solutions to IHC Reproducibility Challenges at KSP 2025
Editor2025-11-20T11:12:06+00:00November 17, 2025|
AIVIS Showcased AI-powered Pathology Innovations at Pathology Vision 2025 in San Diego
Editor2025-10-24T08:35:09+00:00October 21, 2025|
AIVIS Wins First Best Poster Prize at ECP2025
Editor2025-10-01T10:37:48+00:00September 25, 2025|
AIVIS Partners with NAVER Cloud to Expand Access to AI-Powered Pathology Tools
Editor2025-08-11T17:24:18+00:00July 31, 2025|









Reviews
There are no reviews yet.